LMAT

Business Context and Reporting Period

Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2007
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices for vascular surgery, including stent grafts, endovascular accessories, and surgical instruments. The company operates as a single segment with sales primarily in the United States, Europe, and Japan. In April 2007 (subsequent to the reporting period), the company acquired assets from Cardiovascular Innovations, LLC.

Key Financial Metrics

Liquidity: As of March 31, 2007, the company held $28.6 million in combined cash, cash equivalents, and marketable securities. The company maintains a $5.5 million revolving line of credit with no outstanding balance.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 15% to $9.9 million, driven by a 45% increase in the Endovascular & Dialysis Access category and a 30% increase in international sales (outside US/Canada).
• Profitability Decline: Despite revenue growth, the company reported a net loss of $0.6 million compared to a net income of $0.4 million in the prior year. This was primarily due to a 48% increase in Sales and Marketing expenses and a 45% increase in R&D expenses.
• Operating Expenses: Total operating expenses rose 43% to $8.3 million. Sales and marketing costs increased by $1.6 million due to the expansion of the sales force (from 38 to 49 representatives) and increased marketing activities.
• Cash Flow: Net cash used in operating activities was $1.9 million, a reversal from the $0.7 million provided in the prior year. This was driven by increased inventory levels ($1.0 million) and accounts receivable ($0.6 million) to support growth and new distribution agreements.
• Interest Income: Net interest income was $0.4 million, a significant improvement from net interest expense of $46,000 in the prior year, resulting from the investment of IPO proceeds in interest-bearing securities and the elimination of debt.

Guidance, Outlook, and Risks

Management Commentary: Management attributes the loss to strategic investments in sales force expansion, R&D (including the launch of the Pruitt F3 Carotid Shunt), and the costs associated with being a public company. The company expects to continue operating with a net operating loss in the near term to fund growth.

Outlook: The company believes its current cash and marketable securities ($28.6 million) are sufficient to meet working capital and capital expenditure needs for at least the next twelve months. Future capital requirements may necessitate additional equity or debt financing, particularly for acquisitions.

Risks and Contingencies:

• Market Risk: Approximately 40% of sales are denominated in foreign currencies (primarily Euro), exposing the company to exchange rate fluctuations. The company does not currently hedge this exposure.
• Regulatory and Clinical: Success depends on obtaining and maintaining regulatory clearances (FDA) and achieving favorable results from clinical studies.
• Competition: The medical device market is highly competitive, and the company faces risks from new technologies and larger competitors.
• Tax Matters: The company adopted FIN 48 effective January 1, 2007. It has recorded a liability of approximately $0.4 million for unrecognized tax benefits and is subject to IRS examination for 2004 and 2005 returns (settled in April 2007).

Investor Verification Checklist

• Expense Trajectory: Verify if the 48% increase in sales and marketing expenses yields proportional revenue growth in subsequent quarters to justify the operating loss.
• Inventory Levels: Monitor inventory build-up ($7.1 million vs. $6.1 million prior year) to ensure it aligns with sales demand and does not lead to future write-downs.
• International Growth: Confirm the sustainability of the 30% growth in international sales, particularly regarding the new Endologix Powerlink System distribution agreement in Europe.
• Cash Burn Rate: Assess the $1.9 million operating cash outflow against the $28.6 million cash reserve to determine runway without additional financing.
• Subsequent Acquisition: Review the integration and performance of the Cardiovascular Innovations, LLC assets acquired in April 2007.